Phase I Feasibility Trial Opens: THRIVE-CAR-T Digital Support App for Patients Receiving CAR-T Cell Therapy — What Clinicians Need to Know

References

1. 1.Cappell, K. M., & Kochenderfer, J. N. (2021). Long-term outcomes following CAR T cell therapy: what we know so far. Nature Reviews Clinical Oncology, 18(7), 473-488. https://doi.org/10.1038/s41571-021-00564-x
2. 2.Johnson, P. C. (2024). Randomized Controlled Trial of a Supportive Care Digital Application (THRIVE-CAR-T) for Patients Receiving CAR-T Cell Therapy. ClinicalTrials.gov. NCT06665295. https://clinicaltrials.gov/study/NCT06665295
3. 3.June, C. H., O'Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018). CAR T cell immunotherapy for human cancer. Science, 359(6382), eaar6711. https://doi.org/10.1126/science.aar6711
4. 4.Rubanovich, C. K., Mohr, D. C., & Schueller, S. M. (2017). Health app use among individuals with symptoms of depression and anxiety: A survey study with thematic coding. JMIR mHealth and uHealth, 5(4), e7603. https://doi.org/10.2196/mhealth.7603
5. 5.Santomasso, B. D., Park, J. H., Salloum, D., Riviere, I., Flynn, J., Mead, E., ... & Brentjens, R. J. (2018). Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discovery, 8(8), 958-971. https://doi.org/10.1158/2159-8290.CD-17-1319
6. 6.Therapeutic Goods Administration. (2023). CAR-T cell therapy products approved in Australia. Australian Government Department of Health. https://www.tga.gov.au/products/medicines/prescription-medicines/biologicals